Phase II study to evaluate the efficacy and safety of rilotumumab and bevacizumab (BEV) in subjects with recurrent malignant glioma (MG) von Affronti, Mary Lou, Desjardins, Annick, Friedman, Henry S., Peters, Katherine B., Herndon II, James E, McSherry, Frances, Lipp, Eric S, Brickhouse, Alise, Massey, Woody C, Miller, Elizabeth, Cheshire, Sprague, Cone, Christina, Kalinowski, Katherine H, Kim, Jung-Young, Lay, Harry H, Poillucci, Victoria, Southerland, Cindy, Tetterton, Jill, Vredenburgh, James J

Volltext